Insider Selling: ACADIA Pharmaceuticals Inc. (ACAD) EVP Sells 36,558 Shares of Stock

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) EVP Glenn Baity sold 36,558 shares of the company’s stock in a transaction on Monday, January 29th. The stock was sold at an average price of $32.39, for a total transaction of $1,184,113.62. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Glenn Baity also recently made the following trade(s):

  • On Tuesday, January 2nd, Glenn Baity sold 74,321 shares of ACADIA Pharmaceuticals stock. The stock was sold at an average price of $30.14, for a total transaction of $2,240,034.94.

ACADIA Pharmaceuticals Inc. (NASDAQ ACAD) traded down $0.74 during midday trading on Wednesday, reaching $29.91. 1,142,554 shares of the company’s stock traded hands, compared to its average volume of 1,920,000. ACADIA Pharmaceuticals Inc. has a twelve month low of $25.06 and a twelve month high of $41.20. The stock has a market capitalization of $3,660.00, a price-to-earnings ratio of -12.16 and a beta of 3.79.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last posted its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.53) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.63) by $0.10. ACADIA Pharmaceuticals had a negative net margin of 320.71% and a negative return on equity of 67.68%. The business had revenue of $35.58 million during the quarter, compared to analyst estimates of $32.03 million. During the same period in the prior year, the business posted ($0.61) earnings per share. The company’s revenue was up 571.3% on a year-over-year basis. equities research analysts forecast that ACADIA Pharmaceuticals Inc. will post -2.41 earnings per share for the current year.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in ACADIA Pharmaceuticals by 30.6% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,403 shares of the biopharmaceutical company’s stock valued at $223,000 after buying an additional 1,733 shares during the period. Chicago Equity Partners LLC purchased a new stake in ACADIA Pharmaceuticals during the fourth quarter valued at about $237,000. SG Americas Securities LLC boosted its position in ACADIA Pharmaceuticals by 1,371.1% during the fourth quarter. SG Americas Securities LLC now owns 63,934 shares of the biopharmaceutical company’s stock valued at $1,925,000 after buying an additional 59,588 shares during the period. Steward Partners Investment Advisory LLC purchased a new stake in ACADIA Pharmaceuticals during the fourth quarter valued at about $200,000. Finally, State of Alaska Department of Revenue purchased a new stake in ACADIA Pharmaceuticals during the fourth quarter valued at about $219,000. Institutional investors and hedge funds own 94.09% of the company’s stock.

Several research analysts recently issued reports on the stock. BidaskClub upgraded shares of ACADIA Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, January 25th. Zacks Investment Research lowered shares of ACADIA Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, January 24th. Goldman Sachs Group reiterated a “neutral” rating and issued a $45.00 target price on shares of ACADIA Pharmaceuticals in a research report on Friday, October 6th. Bank of America upped their target price on shares of ACADIA Pharmaceuticals from $40.00 to $46.00 and gave the stock a “positive” rating in a research report on Thursday, October 5th. Finally, Cowen reiterated a “buy” rating and issued a $46.00 target price on shares of ACADIA Pharmaceuticals in a research report on Tuesday, November 7th. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and ten have issued a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $48.86.

ILLEGAL ACTIVITY WARNING: “Insider Selling: ACADIA Pharmaceuticals Inc. (ACAD) EVP Sells 36,558 Shares of Stock” was reported by American Banking News and is owned by of American Banking News. If you are viewing this report on another domain, it was illegally stolen and republished in violation of US & international trademark & copyright laws. The legal version of this report can be accessed at https://www.americanbankingnews.com/2018/01/31/insider-selling-acadia-pharmaceuticals-inc-acad-evp-sells-36558-shares-of-stock.html.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. Its lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PD Psychosis).

Insider Buying and Selling by Quarter for ACADIA Pharmaceuticals (NASDAQ:ACAD)

Receive News & Ratings for ACADIA Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply